Roth MKM keeps a Buy rating while adjusting the firm’s price target to $40 from $11. The price target change reflects the company’s impending latiglutenase acquisition, recent 1 for 20 reverse split, and recent warrant exercise transaction, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FWBI:
- First Wave BioPharma Inc trading resumes
- First Wave BioPharma Inc trading halted, volatility trading pause
- First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
- First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
- First Wave BioPharma to sell Niclosamide program to treat IBD
